| Literature DB >> 31390551 |
Alexandra Collin de l'Hortet1, Kazuki Takeishi2, Jorge Guzman-Lepe1, Kazutoyo Morita1, Abhinav Achreja3, Branimir Popovic1, Yang Wang4, Kan Handa1, Anjali Mittal5, Noah Meurs3, Ziwen Zhu3, Frank Weinberg6, Michael Salomon7, Ira J Fox8, Chu-Xia Deng9, Deepak Nagrath10, Alejandro Soto-Gutierrez11.
Abstract
The mechanisms by which steatosis of the liver progresses to non-alcoholic steatohepatitis and end-stage liver disease remain elusive. Metabolic derangements in hepatocytes controlled by SIRT1 play a role in the development of fatty liver in inbred animals. The ability to perform similar studies using human tissue has been limited by the genetic variability in man. We generated human induced pluripotent stem cells (iPSCs) with controllable expression of SIRT1. By differentiating edited iPSCs into hepatocytes and knocking down SIRT1, we found increased fatty acid biosynthesis that exacerbates fat accumulation. To model human fatty livers, we repopulated decellularized rat livers with human mesenchymal cells, fibroblasts, macrophages, and human SIRT1 knockdown iPSC-derived hepatocytes and found that the human iPSC-derived liver tissue developed macrosteatosis, acquired proinflammatory phenotype, and shared a similar lipid and metabolic profiling to human fatty livers. Biofabrication of genetically edited human liver tissue may become an important tool for investigating human liver biology and disease.Entities:
Keywords: NAFLD; NASH; SIRT1; cellular engineering; hepatic differentiation; human fatty liver; human iPSCs; liver metabolism
Mesh:
Substances:
Year: 2019 PMID: 31390551 PMCID: PMC6691905 DOI: 10.1016/j.cmet.2019.06.017
Source DB: PubMed Journal: Cell Metab ISSN: 1550-4131 Impact factor: 27.287